Locust Walk released its Q2 2018 report on the latest Trends in Biopharma Transactions. Download it now (bit.ly/Q2-18Biopharma). In this quarter’s report you can find an overview and analysis of the US, Europe, Japan, and China. Learn the... bit.ly/Q2-18Biopharma

Q2 2018 Medtech M&A activity trended towards industry consolidation, allowing major players to broaden device and diagnostic portfolios. Read Locust Walk's latest Medtech Transactions Report: bit.ly/Q2-18Medtech bit.ly/Q2-18Medtech

We had a good discussion about a range of topics. I look forward to the next Board Meeting in June in Boston.

At BIO CEO & Investor Conference this week in NYC, Sapna Srivastava asked Geoff Meyerson from Locust Walk about the current market for capital raises. #bioceo19 #fireside #biotech #capitalraising #funding

facebook.com/locustwalkptrs…

facebook.com/locustwalkptrs…

facebook.com/locustwalkptrs…

New Locust Walk blog post! Despite the inherent challenges of fundraising, the current climate is quite favorable. In this post, we’ll explore why it’s favorable and how to characterize the current funding environment to share a few deal term... lnkd.in/dzshV7B

Hayato Watanabe, SVP, Head of Asia, at Locust Walk is participating in a panel discussion at the Bio Asia International Conference on Tuesday, ​March 5th in Tokyo, Japan. The panel titled "Market Outlook–Finding Opportunities During Global Trade... lnkd.in/d8XU2Xu

This just in! Locust Walk appoints Howard Hechler, Vice President of Medtech. Based in the firm's Boston, MA office, Howard will be... prnewswire.com/news-releases/…

Download our complimentary whitepaper, The Asia Factor, and discover how a smart deal maker "plays" this region and optimizes capital raising and strategic deal making opportunities. bit.ly/TheAsiaFactorW… #biopharma... bit.ly/TheAsiaFactorW…

Great to hear from my Locust Walk colleague Hunt Henrie that orthopedic innovation is picking up and M&A activity is increasing. lnkd.in/eBSeEcd

"The sheer size of the domestic market and unmet medical needs in China combined with the maturing regulatory and commercial environment creates an unparalleled opportunity for homegrown innovation and in-licensed... facebook.com/121420397307/p…

2019 American Academy of Orthopedic Surgeons (AAOS) meeting was all about M&A and promising new technology including robotics, software, and digital surgery. Click here for more analysis from Hunt Henrie of Locust Walk! #aaos2019 #orthopedics #mergers... buff.ly/2FswiQ8

2018 was a record year for venture capital financings into biotech, and a record number of institutional funds raised specifically for the life sciences. If you are looking to start fund raising this is a must read:... bit.ly/TrendsInVentur…

Looking to maximize the value of your company or asset? Geoff Meyerson, Chris Ehrlich, and Andrew Meyerson of Locust Walk put together a whitepaper addressing just that, "The Art of the Multi-Track Deal," sharing insight into how multiple deal options... lnkd.in/d3mddY3

My Locust Walk colleagues Chris Ehrlich, Andrew Meyerson and I discuss the optimal way to maximize value by running the right process. Feedback and comments welcome. #integration #multitrack lnkd.in/gUfxq6D

New Locust Walk team members Neil Higgins and Turner Grant along with group head Brian W. Coleman are doing something truly unique in the life science industry namely combining upfront strategic planning, storytelling and valuation work with comprehensive…lnkd.in/gy9ATJm

Join me for a panel discussion about our recent thought piece about the strategic implications for #biopharma on #covid19. Submit questions in advance if you'd like them address on the webinar. lnkd.in/g8_B4YW

Rates will not drop this year. Rates to drop in 2024. M&A=good; approvals=good. IRA & Washington pressure=bad. Rates that haven’t peaked=bad. With the biotech market down this year, that will make it harder to get capital for private companies vs investing in public companies.